Patient Caregiver Connection: Novel Approaches to Optimizing Outcomes in COPD

 


Release Date: June 29, 2018
Expiration Date: June 29, 2019
Media: Internet - based

Activity Overview

More than 15 million Americans have been diagnosed with chronic obstructive pulmonary disease (COPD), and another 12 million have the disease but remain undiagnosed. Spirometry is an effective diagnostic modality, but is underused by health care professionals. Fortunately, a new approach identifies patients who are most likely to have an abnormal spirometry. In keeping with the National Institutes of Health COPD Action Plan that was released in 2017, the COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk, or simply the CAPTURE questionnaire, helps clinicians identify patients with COPD early. Across the United States and globally, most experts recommend relying on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD to manage the disease. While spirometry is clearly an essential diagnostic element, clinicians must also consider patients’ severe breathlessness and acute exacerbations, as well as step-up care. Patients may need inhaled or systemic corticosteroids, supportive care, and perhaps hospitalization. Pharmacologic therapy can reduce COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance. Most patients with COPD use inhalers to control their disease. People with moderate to very severe COPD may benefit from nebulized treatments that allow them to breathe normally while taking medication.

During this Patient Caregiver Connection Medical Crossfire®, a multidisciplinary panel of expert faculty will introduce available tools, discuss guidelines, and suggest strategies to help improve care for people with COPD. This activity is enhanced by a patient’s own story and perspective, from diagnosis to daily challenges and advice for anyone experiencing COPD.

Acknowledgement of Commercial Support

This activity is supported by an independent educational grant from Sunovion Pharmaceuticals, Inc. 

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This activity is directed to pulmonologists, respiratory therapists, internal medicine and primary care physicians, geriatricians, and researchers; other health care professionals interested in the treatment of COPD are invited to participate.

Learning Objectives

At the completion of this activity, you should be better prepared to:

  • Discuss the symptoms and risk factors for COPD, in addition to the importance of early recognition and routine spirometry in at-risk patients
  • Explain the impact of disease severity and patient symptoms, needs, and preferences in providing individualized treatment with goals of slowing the decline of lung function, providing symptomatic relief, and managing disease-related exacerbations
  • Review the efficacy and safety of new and emerging therapeutic options for patients with COPD
  • Apply comprehensive knowledge to appropriately educate and counsel patients with COPD

Faculty, Staff, and Planners' Disclosures

Moderator

Paul P. Doghramji, MD, FAAFP
Attending Physician, Collegeville Family Practice
Medical Director, Health Services, Ursinus College
Collegeville, Pennsylvania
Cofounder, Brookside Family Practice and Pediatrics
Assistant Medical Director, Health Services, Hill School
Pottstown, Pennsylvania



Disclosure: No relevant financial relationships with commercial interests

Program Chair

Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York
 
Disclosure: Grant/Research Support: AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim.  Speakers Bureau: Boehringer Ingelheim, Miller, NACE, Novartis. Consultant: AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Proterix Bio, Genentech, Novartis, Pearl, Theravance.

Program Faculty

Michael B. Foggs, MD, FAAAI, DFACAAI, FCCP
Chief of Allergy and Immunology
Advocate Medical Group
Advocate Health Care
Chicago, Illinois
 
 

Disclosure: Consultant: AstraZeneca, Circassia. Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Circassia, Novartis, Sunovion.


Alanna E. Kendig, FNP-BC, CCRN
Nurse Practitioner
Pulmonary and Critical Care Medicine
Weill Cornell Medicine
New York, New York
Instructor of Practice, Nursing
College of Mount Saint Vincent
Riverdale, New York
 
Disclosure: No relevant financial relationships with commercial interests

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

 






Become a Member

Forgot Password?
Filter By